89bio, Inc. (ETNB) Misses Q2 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
August 7, 2025 4:05 PM EDTENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH)
ENTRUST Phase 3 topline data in severe hypertriglyceridemia (SHTG) expected in 1Q 2026
Cash, cash equivalents, and marketable securities totaled $561.2 million as of June 30, 2025
SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today... More
